Injection for mastitis

An injection and mastitis technology, applied in the field of injections for mastitis, can solve the problems of increased dosage of the main agent, low dissolution, and low absorption of the main agent, and achieves improved absorption, short residual time, and improved dissolution. Effect

Active Publication Date: 2008-01-16
NIPPON ZENYAKU KOGYO CO LTD
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Therefore, the aforementioned conventional injection preparations for mastitis have the following problems: the main ingredient has low elution (release) from the oily base, so the absorption of the main ingredient is also low, and as a result, sufficient pharmacological effects cannot be expected from the main ingredient. ; Further, due to low dissolution and absorption, the actual dosage of the main agent increases, and the residual time in the animal body prolongs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Injection for mastitis
  • Injection for mastitis
  • Injection for mastitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] An injection agent 1 (3 g) having a composition in Table 1 was prepared using octanoic acid monoester Sunsoft 707 (manufactured by Sun Chemical Co., Ltd.) having 8 carbon atoms as MCM.

[0036] [Table 1]

[0037] Injection 1

[0038] Main ingredient Cefazolin (CEZ) 150mg (potency)

[0039] MCM 75mg (2.5% by weight)

[0040] Additive Edible Blue No. 1 25mg

[0041] Oily base rapeseed oil balance

[0042] Total 3g

[0043] The above-mentioned injection 1 was filled into a plastic syringe for mastitis ointment commonly used by the applicant company, and an injection for mastitis was trial-produced. The injection preparation 1 prepared as a trial showed physical properties suitable for use as an injection preparation for mastitis.

[0044] 1. Dissolution test carried out by changing the ratio of MCM

[0045] For injection 1, according to the dissolution test method No. 2 (paddle method) of the Japanese Pharmacopoeia General Test Method, phosphate buffer (pH 6.5) (4.8...

Embodiment 2

[0104] [Table 4]

[0105] Injection 2

[0106] Main ingredient Cefazolin (CEZ) 75mg (potency)

[0107] MCM 75mg (2.5% by weight)

[0108] Additive Edible Blue No. 1 25mg

[0109] Oily base rapeseed oil balance

[0110] Total 3g

[0111] The above-mentioned injection 2 was filled into a plastic syringe for mastitis ointment commonly used by the applicant company, and an injection for mastitis was trial-produced. The injection preparation 2 prepared as a trial showed physical properties suitable for use as an injection preparation for mastitis.

Embodiment 3

[0113] [table 5]

[0114] Injection 3

[0115] Main ingredient Cefazolin (CEZ) 50mg (potency)

[0116] MCM 75mg (2.5% by weight)

[0117] Additive Edible Blue No. 1 25mg

[0118] Oily base rapeseed oil balance

[0119] Total 3g

[0120] The above injection 3 was filled into a plastic syringe for mastitis ointment commonly used by the applicant company, and the injection for mastitis was trial-produced. The trial-produced injection 3 exhibited physical properties suitable for use as an injection for mastitis.

[0121] 1. Dissolution test carried out by changing the ratio of MCM

[0122] Figure 4 shows the dissolution rate of the injection 1, injection 2, injection 3 and the control drug Sephamethin QR, and the dissolution rate is shown in Figure 5. As shown in Fig. 5, the injection 3 of the CEZ1 / 3 formulation containing MCM started to dissolve immediately, and dissolved about 100% in 10 minutes. About 100% of CEZ containing MCM was dissolved in 40 minutes with the same ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An injection for mastitis which contains a main ingredient, a medium-chain fatty acid monoglyceride and an oily base, wherein the diffusion and dispersion of the main ingredient is accelerated by the medium-chain fatty acid monoglyceride so that the elution properties of the main ingredient are improved and the absorbability thereof is elevated. Thus, it is expected that the above-described injection exerts an immediate action and has a short retention time and, therefore, the main ingredient can be effectively utilized while reducing waste, compared with the existing injections for mastitis.

Description

technical field [0001] The present invention relates to an injection agent (injection agent) for mastitis (mastitis) that improves the pharmacological action of a main ingredient by improving the elution property of the main ingredient from a base. Background technique [0002] Livestock such as cows and goats that have been raised for milk have historically suffered from mastitis. Mastitis is an infection of the udder of livestock with or associated with Staphylococcus (eg, Staphylococcus aureus (S. aureus) ), Escherichia coli (Escherichia coli ), or other pathogens that cause inflammation . The incidence of mastitis is high, resulting in reduced milk volume, reduced milk quality, and increased frequency of removal of sick animals' thinning (jian引き) from the milk-producing herd. Therefore, mastitis is a matter of life and death for practitioners of milk production. serious disease of the problem. [0003] Therefore, in order to prevent the onset of mastitis, practitioner...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/14A61K9/08A61K31/22A61K31/245A61K31/43A61K31/431A61K31/546A61K31/7036A61K47/44A61P15/00
CPCA61K31/7036A61K47/14A61K47/44A61K31/546A61K9/0041A61K31/245A61K31/22A61K9/0019A61K31/43A61K31/431A61P15/00A61P15/14A61P31/00A61P31/04A61K31/20
Inventor 塚田纯子大桥英一松永富雄
Owner NIPPON ZENYAKU KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap